Peptides Are Coming to Telehealth Checkouts. Here Is What to Look For.
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Big telehealth brands have started saying they'll sell peptides. Hims & Hers told investors it plans to start offering some by the end of the year, naming sermorelin, glutathione and NAD+ as examples (Fierce Healthcare). Noom bought a compounding pharmacy to do the same (MobiHealthNews). When these show up next to the GLP-1 you already buy, they'll look like the same kind of product. Some will be. Some won't. This is how to tell the difference.
Who This Helps
You use a telehealth service, or you're thinking about one. You've seen peptides talked about online. You want to know what's legal, what's safe, and what a seal on a website does and doesn't mean. We're not here to scare you off peptides. We're here to help you buy with your safety in mind.
What changed this summer
In July, an FDA advisory panel voted on seven peptides. The FDA staff had said no to all of them. The panel disagreed on six. It voted yes on BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax (AJMC). That vote made headlines. It did not change the law, so these are not (yet) legal to compound and purchase.
A panel vote is advice to the FDA. The FDA still has to write a rule, take public comments, and finish it. The last group the FDA finished this process with took over two years. The group after that was proposed in 2019 and still isn't final. As of this writing, no rule has been proposed for these six. The panel meets again before the end of February 2027 to discuss other peptides (FDA).
So right now, none of those six peptides has a clear legal path for a pharmacy to make them. Some lawyers call it a gray area. That's a fair description. We covered the panel vote itself when it happened.
The peptides that do have a path
A few peptides can already be compounded by a licensed pharmacy with a prescription. They fall into two groups.
The first group is on an FDA list of substances still under review. For these, the FDA has said it doesn't plan to act against pharmacies that make them, as long as other rules are met. NAD+ and glutathione are on it. So is GHK-Cu, as long as it's not injected (FDA).
The second group are peptides that are, or were, the active ingredient in an approved drug. Tesamorelin is the drug Egrifta. Sermorelin was approved years ago as Geref, which is no longer sold. Pharmacies and lawyers argue these have a legal route that BPC-157 does not. The FDA hasn't said so in plain terms, so treat this as the industry's view, not a settled fact.
That's why Hims named sermorelin, glutathione and NAD+. Those are the ones with a path. On its earnings call it said it has started testing BPC-157 but will wait for the FDA to act before selling it (Hims & Hers Q2 2026 earnings call).
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
What the FDA has been cracking down on
Before and after the panel vote, the FDA was sending warning letters. In March and again in August, it went after sellers of peptides labeled "for research use only" (FDA). These sites say the product isn't for people. Then their product pages make health claims. Some sell mixing solutions for home use (called BAC water), a guide and a dose calculator right next to the vials.
The FDA's view is that the whole website counts, not just the label. If the site claims health effects and helps you use the product, it's a drug for people. The letters named products like tirzepatide, retatrutide, and tesamorelin sold this way (FDA).
None of these peptide letters went to a telehealth company. They went to websites selling vials with no doctor and no pharmacy. Telehealth firms did get about 30 FDA letters in March. Those were about how they sold compounded GLP-1s, not about peptides (National Law Review). So the divide isn't peptide versus no peptide. It's prescription and pharmacy versus a vial in the mail.
The seal you'll see, and what it means
Many telehealth sites that sell GLP-1s carry a LegitScript seal, and it's required to share your business details on any other platform like Facebook, Instagram, and Tiktok. Google requires it before they can run ads (Google Ads policy). So what does it check?
LegitScript checks that the business is licensed, that a real clinician sees you before you get a prescription, that the pharmacy it uses is legitimate, that the drugs come from proper sources, and that it doesn't sell drugs that aren't allowed (LegitScript). That last part is key. LegitScript has said BPC-157, TB-500, retatrutide and cagrilintide are not currently eligible. Selling or promoting them breaks the rules, and LegitScript says doing it through a partner still creates a problem for the certification (LegitScript).
What it doesn't do: test the product. LegitScript's standards cover who sells it and how, not whether the peptide works or is safe. It's also a private company that the seller pays. So the seal tells you the business follows the rules. It doesn't tell you anything about the peptide itself.
One more thing. A seal image can be copied. LegitScript says to check its own site to see if the certification is real. Don't trust the picture alone.
Green flags when you see a peptide for sale
- A licensed clinician sees you first. Not a form. A real visit, even if it's online.
- A named pharmacy fills it. You can look it up with your state board (state boards directory). We wrote about why the license beats a lab report.
- It's one of the peptides with a legal path. Sermorelin, tesamorelin, NAD+, glutathione, or GHK-Cu as a cream.
- The seal checks out on LegitScript's own site. Necessary, but not a standalone check.
Red flags
- "Research use only" on anything meant for you to take. The FDA looks at the whole site. If it makes health claims and helps you use the product, the label doesn't protect anyone.
- No clinician, or a rubber-stamp approval. LegitScript requires a real clinical visit before a prescription. A two-minute form isn't that if you don’t have a clinician name attached to your prescription.
- BPC-157 or TB-500 for sale today. No pharmacy has a clear path to make these yet. If a site sells them, ask how.
- Words like "FDA-approved" or "clinically proven." No compounded peptide is FDA-approved. A site that says so has its facts wrong.
- A waiver that calls it "research-grade." One state medical board has said a waiver doesn't make it legal (Alabama Reporter).
What's actually known about these peptides
Less than the hype suggests. For BPC-157, the FDA found five small human studies. It said none was good enough to show the drug works or is safe. For TB-500, KPV and MOTS-c, the FDA found no human data it qualified as reputable. Not bad data. None.
That doesn't mean they're harmful. It means no one has checked properly. The FDA did flag worries, like whether injected peptides might set off an immune response or clump together. Panel members who voted yes said they did so partly to pull people away from the gray market, where quality is anyone's guess (The Hill). That's a reasonable goal. It's also a sign of how thin the evidence is.
Final Takeaway
Peptides at checkout aren't a problem by themselves. The question is how they got there. A prescription from a real clinician, filled by a licensed pharmacy, for a peptide with a legal path, is one thing. A vial labeled "research only" with a dosing chart is another. The seal on the site tells you about the business, not the product. Ask how the peptide is legal to sell. A good seller will have an answer.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Did the FDA approve BPC-157?
No. An advisory panel voted to recommend it in July. The FDA has not acted on that vote. No rule has been proposed. Nothing has changed in the law yet.
What does a LegitScript seal mean?
The business is licensed, uses real clinicians, uses a legitimate pharmacy, and doesn't sell drugs that aren't allowed. It doesn't mean the product was tested. Check the seal on LegitScript's own site.
Are peptides safe?
For BPC-157, TB-500, KPV and MOTS-c, nobody knows. The FDA found little or no human data on them. That's different from finding harm. It means the testing hasn't been done. Tesamorelin and sermorelin have more history behind them.
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Even at no cost, 10% of new prescriptions go unfilled. See where reducing what patients owe actually changes behavior, and where it does not.
An Australian lab tested 18 vials sold as retatrutide. One matched its label. See what the dosing errors were and why a purity test proves little.
Wondering about adding peptides to your GLP-1? Here is what is safe, what is not yet legal, and what your doctor needs to know.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.